Anti-PCSK9 (C-terminal) polyclonal antibody

Name: Anti-PCSK9 (C-terminal) polyclonal antibody
SKU: DPAB-DC1220
Rating: 5 (1 reviews)

Goat anti-Human PCSK9 (C-terminal) polyclonal antibody for WB, IHC-P, ELISA

Write a review

COA

SDS

Datasheet

Summary

Specifications

Species Reactivity

Human

Immunogen

A synthetic peptide corresponding to C-terminus of human PCSK9. The sequence is CRSRHLAQASQELQ

Conjugate

Unconjugated

Applications

Application Notes

ELISA: 1:16000; WB: 0.3 μg/mL; IHC-P: 2-6 μg/mL. & The optimal working dilution should be determined by the end user.

Target

Alternative Names

PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein;

Entrez Gene ID

255738

UniProt ID

Q8NBP7

Product Background

Antigen Description

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants.

Citations

Have you cited DPAB-DC1220 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

CLINICAL USE, INSURANCE APPROVAL, AND LIPID LOWERING OF PCSK9 INHIBITORS IN A LARGE HEALTH SYSTEM

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Authors: Sheth, Samip; Cuccolo, Niccole; Vassalo, Regina; Blaine, Natalie; Wharton, Donald; Favatella, Joseph; Hossain, Erik; Hajj, Jihane; Webb, Gayley; Bajaj, Archna; Soffer, Daniel; Rader, Daniel; Jacoby, Douglas

Abstract

Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors

CURRENT MEDICINAL CHEMISTRY

Authors: Panagiotopoulou, Olga; Chiesa, Scott T.; Tousoulis, Dimitrios; Charakida, Marietta

Abstract

Genetic, experimental and clinical studies have consistently confirmed that inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) can result in significant lowering of LDL-C and two fully human PCSK9 monoclonal antibodies have received regulatory approval for use in high-risk patients. Co-administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term safety profiles. While results from Phase III clinical trials provided significant evidence about the role of PCSK9 inhibitors in reducing cardiovascular event rates, their impact on mortality remains less clear. PCSK9 inhibitor therapy can be considered for high-risk patients who are likely to experience significant cardiovascular risk reduction.